Jagsonpal Pharma's Buyback Approved: 1.6 Million Shares at ₹250 Each
Jagsonpal Pharmaceuticals Limited's shareholders approved a buy-back of up to 1.6 million equity shares at ₹250 per share, totaling ₹40 crores. The resolution passed with 99.994% of votes in favor during postal ballot and remote e-voting, which concluded on April 24, 2026.
A buy-back of this size can positively impact shareholder value and EPS, but it is a medium impact as it is a specific corporate action and not a fundamental business change.
The sentiment is positive as the company successfully obtained shareholder approval for its proposed buy-back of equity shares, which is generally viewed favorably by the market.
Jagsonpal Pharmaceuticals Limited has announced the successful passing of a special resolution for the buy-back of equity shares through postal ballot and remote e-voting. The resolution, confirmed by the members with the requisite majority, allows for the buy-back of up to 16,00,000 fully paid-up equity shares of face value ₹2 each, at a price of ₹250 per share. This buy-back aggregates to an amount not exceeding ₹40 crores.
The voting results, submitted by Scrutinizer Ayush Khandelwal & Associates, indicate that the resolution was deemed passed on Friday, April 24, 2026, the last day of remote e-voting. Out of the total valid votes cast, 99.994% were in favour of the buy-back, with only 0.006% voting against it. The company has also uploaded these results on its website and the National Securities Depository Limited (NSDL) website for public access.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under buyback announcement. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.